SCHEMBL548925

SCHEMBL548925

Oc1cc(O)c(C23CC4CC(CC(C4)C2)C3)c(C23CC4CC(CC(C4)C2)C3)c1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
POLB P06746 1/20 0.52
GAA P10253 1/20 0.52
GFER P55789 1/20 0.52
EPHX2 P34913 2/20 0.39
MAPT P10636 3/20 0.38
THRB P10828 2/20 0.38
USP2 O75604 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 3/20 0.38
ALDH1A1 P00352 2/20 0.38
NPC1 O15118 1/20 0.37
RARB P10826 4/20 0.36
RARA P10276 3/20 0.36
RARG P13631 3/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL549511 0.90 MEN1 (0.47) MEN1KMT2APOLBGAAGFER
SCHEMBL548693 0.88 MEN1 (0.46) MEN1KMT2APOLBGAAGFER
SCHEMBL549767 0.86 MEN1 (0.44) MEN1KMT2APOLBGAAGFER
SCHEMBL547956 0.85 MEN1 (0.47) MEN1KMT2APOLBGAAGFER
SCHEMBL3762662 0.84 MEN1 (0.50) MEN1KMT2APOLBGAAGFER
SCHEMBL548653 0.84 MEN1 (0.59) MEN1KMT2APOLBGAAGFER
SCHEMBL548727 0.83 MEN1 (0.63) MEN1KMT2APOLBGAAGFER
SCHEMBL548654 0.82 MEN1 (0.44) MEN1KMT2APOLBGAAGFER
SCHEMBL27544130 0.81 MEN1 (0.47) MEN1KMT2APOLBGAAGFER
SCHEMBL549792 0.81 MEN1 (0.43) MEN1KMT2APOLBGAAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110614-B2 Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative IDEMITSU KOSAN CO., LTD. (JP) 2012-02-07 US disclosed
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2010-03-04 US disclosed
EP-2090563-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE ARCN1, RTN3, CHRNA3 MEN1 3412/4885KMT2A 3737/4885POLB 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.